They are trying to make out that the Phase II trial was NOT a total failure... because it was successful in proving that maybe standard care is only good enough for the time being given that standard care has yet to be tested as rigorously as FTT's product.
Now they are raising money in the hope of making an acquisition (possibly in the technology sector)... to achieve what? A means to an end? Under the advisement of who... Troy Collinson???
It could be something big... or it could be something fishy! Take your pick.
At these levels its not much of a risk, but really this company should be held to account.
FTT Price at posting:
0.3¢ Sentiment: Hold Disclosure: Held